吉林省西点药业科技发展股份有限公司 2024 年度董事会工作报告 公司以市场需求为导向，加大对新技术的研发和技术创新的投入，提升研发 水平。首次公开发行募集资金投资项目"研发中心建设项目"于2024年2月已顺 2024 年度董事会工作报告 2024 年度，吉林省西点药业科技发展股份有限公司（以下简称"公司"）董 事会全体董事严格遵守《中华人民共和国公司法》（以下简称《公司法》）《中 华人民共和国证券法》（以下简称《证券法》）等法律法规以及《公司章程》《董 事会议事规则》等规章制度的规定，认真贯彻执行股东大会通过的各项决议，积 极推进董事会各项决议的实施，不断规范公司法人治理结构，恪尽职守、勤勉尽 责，为董事会科学决策和规范运作做了大量富有成效的工作，确保公司稳健发展， 有效地保障了公司和全体股东的利益。 现将 2024 年度董事会主要工作报告如下： 一、2024年度公司整体经营情况 2024年，公司站在新的起点，继续围绕既定"让健康的血液顺畅地流淌，让 家庭祥和安宁充满阳光"发展战略不动摇，保持战略定力，持续加大研发投入力 度，贯彻人才发展战略，优化创新体制机制，加快创新研发成果转化落地，顺应 行业发展趋势， ...

非经营性资金占用及其他关联资金 往来情况专项说明 吉林省西点药业科技发展股份有限公司 容诚专字[2025]100Z1192 号 容诚会计师事务所(特殊普通合伙) 中国·北京 关于吉林省西点药业科技发展股份有限公司 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 非经营性资金占用及其他关联资金往来情况专项说明 容诚专字[2025]100Z1192 号 吉林省西点药业科技发展股份有限公司全体股东： 我们接受委托，依据中国注册会计师审计准则审计了吉林省西点药业科技发 展股份有限公司（以下简称西点药业公司）2024 年 12 月 31 日的合并及母公司资 产负债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表和合并及 母公司所有者权益变动表以及财务报表附注，并于 2025 年 4 月 22 日出具了容诚 审字[2025]100 ...

国泰海通证券股份有限公司 关于吉林省西点药业科技发展股份有限公司 2024 年度内部控制自我评价报告的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为吉林 省西点药业科技发展股份有限公司（以下简称"西点药业"或"公司"）首次公开发 行股票并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《深 圳证券交易所上市公司自律监管指引第 13 号——保荐业务》《深圳证券交易所上 市公司自律监管指引第 2 号-创业板上市公司规范运作》《企业内部控制基本规范》 等法律、法规和规范性文件的要求，对《吉林省西点药业科技发展股份有限公司 2024 年度内部控制自我评价报告》进行了核查，具体情况如下： 一、内部控制评价工作情况 （一）内部控制评价范围 公司按照风险导向原则确定纳入评价范围的业务和事项。 内部控制评价的范围涵盖了公司及其所属子公司的主要业务，重点关注下列 高风险领域：治理架构、组织机构 、发展战略、人力资源、企业文化、内部审计、 会计、资金活动、风险管理、采购业务、资产管理、销售业务、研究与开发、财务 报告、全面预算、合同管理、内部信息传递、信息系统。 纳入评价范围的单位包括： ...

吉林省西点药业科技发展股份有限公司 关于召开 2024 年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）定于 2025 年 5 月 15 日（星期四）14:00 召开 2024 年年度股东大会，本次会议采取现场表决 与网络投票相结合的方式召开，现将有关事项通知如下： 一、 召开会议的基本情况 1、会议届次：2024 年年度股东大会 证券代码：301130 证券简称：西点药业 公告编号：2025-035 表决权。公司股东只能选择现场表决和网络投票中的一种方式，如果同一表决 权出现重复投票表决的，以第一次有效投票表决结果为准。 6、会议的股权登记日：2025 年 5 月 12 日（星期一） 7、出席对象 （1）在股权登记日持有公司已发行有表决权股份的普通股股东或其代理 人；于股权登记日下午收市时在中国证券登记结算有限责任公司深圳分公司登 记在册的公司全体已发行有表决权股份的股东均有权出席股东大会，并可以以 书面形式委托代理人出席会议和参加表决，该股东代理人不必是本公司股东。 2、会议召集人 ...

证券代码：301130 证券简称：西点药业 公告编号：2025-028 吉林省西点药业科技发展股份有限公司 第八届监事会第十一次会议决议公告 经与会监事认真审议并表决，审议了如下事项： （一）审议通过《关于公司<2024 年度监事会工作报告>的议案》 根据公司监事会 2024 年度工作情况，监事会作出了《2024 年度监事会工作 报告》。 本议案尚需提交公司 2024 年年度股东大会审议。 表决结果：同意 5 票，反对 0 票，弃权 0 票。 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、会议召开情况 吉林省西点药业科技发展股份有限公司（以下简称"公司"）第八届监事会 第十一次会议于 2025 年 4 月 22 日 10:30 在长春市卫星路 1471 号公司会议室以 现场结合通讯方式召开。本次会议通知于 2025 年 4 月 12 日以邮件、电话、书面 等方式送达全体监事。会议由监事会主席侯雨霖先生主持，应出席监事 5 名，实 际出席监事 5 名，其中监事王立波、潘贤平、马端香以通讯方式参会并表决。 公司董事会秘书、保荐代表人列席了会议。 会议的召开符 ...

证券代码：301130 证券简称：西点药业 公告编号：2025-027 吉林省西点药业科技发展股份有限公司 第八届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 吉林省西点药业科技发展股份有限公司（以下简称"公司"）第八届董事会 第十一次会议于 2025 年 4 月 22 日 9:30 以现场结合通讯方式在吉林省长春市卫 星路 1471 号公司会议室召开。本次会议通知于 2025 年 4 月 12 日以邮件、电话、 书面等方式送达全体董事。会议由董事长张俊先生主持，应出席董事 9 名，实际 出席董事 9 名，其中以通讯方式参会并表决的董事有孟永宏先生、刘淑敏女士、 申太根先生。 公司监事、高级管理人员、保荐代表人列席了会议。 会议的召开符合《中华人民共和国公司法》和《公司章程》的规定，会议合 法有效。 二、会议审议情况 经与会董事认真审议并表决，审议了如下事项： （一）审议通过《关于公司<2024 年度董事会工作报告>的议案》 根据公司董事会 2024 年度工作情况及公司年度经营状况，董事会作出了 《2024 年度 ...

证券代码：301130 证券简称：西点药业 公告编号：2025-029 1、董事会审议情况 公司于 2025 年 4 月 22 日召开第八届董事会第十一次会议，以 9 票同意、0 票反对、0 票弃权的表决结果审议通过了《关于公司<2024 年度利润分配预案>的 议案》，同意该利润分配预案提交公司 2024 年年度股东大会审议。 2、监事会审议情况 吉林省西点药业科技发展股份有限公司 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要提示： 1、吉林省西点药业科技发展股份有限公司（以下简称"公司"）2024 年度 利润分配预案为：向全体股东每 10 股派发现金股利 2.60 元人民币（含税），不 转增股本，不送红股。 2、公司 2024 年度利润分配预案不触及《深圳证券交易所创业板股票上市规 则》第 9.4 条第（八）项规定的可能被实施其他风险警示情形。 一、审议程序 自 2025 年 1 月 1 日至实施 2024 年度权益分派的股权登记日期间，公司总股 本发生变动的，拟维持每 10 股派 2.60 元（含税）比例不变，相应 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥52,219,200.85, a decrease of 21.72% compared to ¥66,705,459.25 in the same period last year[5] - Net profit attributable to shareholders was ¥8,294,245.85, down 40.94% from ¥14,042,843.67 year-on-year[5] - Basic and diluted earnings per share were both ¥0.1084, representing a decline of 37.63% from ¥0.1738 in the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥7,567,590.00, down 37.26% from ¥12,061,082.58 year-on-year[5] - The weighted average return on equity was 0.88%, down from 1.42% in the previous year[5] - Net profit for the current period is 7,651,948.96, a decrease of 45.5% compared to 14,042,843.67 in the previous period[24] - Operating profit for the current period is 8,862,074.91, down 45.4% from 16,305,235.17 in the previous period[24] - Total comprehensive income for the current period is 7,651,948.96, compared to 14,042,843.67 in the previous period[24] Cash Flow and Assets - The net cash flow from operating activities increased by 76.53% to ¥13,143,660.17, compared to ¥7,445,732.65 in the previous year[5] - The company's cash and cash equivalents decreased to ¥131,726,829.02 from ¥190,678,612.90, reflecting a decline of approximately 30.9%[18] - The company's total liabilities decreased to ¥95,432,165.64 from ¥121,411,576.83, representing a reduction of approximately 21.4%[20] - The ending cash and cash equivalents balance is 131,165,469.74, down from 286,157,567.56 in the previous period[26] - Cash flow from operating activities shows a net increase of 13,143,660.17, up from 7,445,732.65 in the previous period[26] - Investment cash inflow is 285,316,977.35, compared to 238,619,544.48 in the previous period, indicating a significant increase[26] - Cash flow from investment activities shows a net outflow of 71,884,685.94, contrasting with a net inflow of 6,267,827.88 in the previous period[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,165[11] - The largest shareholder, Zhang Jun, holds 25.66% of the shares, totaling 19,627,034 shares[11] - The top 10 unrestricted shareholders include Dingdian Investment Management (Beijing) Co., Ltd. with 6,013,154 shares, Zhang Jun with 4,906,759 shares, and Zhuhai Hengqin Rock Health Technology Co., Ltd. with 3,697,400 shares[12] - The total number of restricted shares held by major shareholders decreased from 22,838,309 to 17,869,050 shares, with 4,969,259 shares released during the period[14] - The company has a consistent action relationship among its major shareholders, including Dingdian Investment Management and Hengqin Runhui Equity Investment Fund[13] - The company reported a 4.83% stake held by Zhuhai Hengqin Rock Health Technology Co., Ltd., amounting to 3,697,400 shares[12] - The company’s major shareholders include Guotou High-tech Investment Co., Ltd. with a 4.25% stake, equivalent to 3,248,997 shares[12] - The company’s major shareholder, Shi Shilin, holds 1,555,900 shares through a margin trading account[13] - The company’s major shareholder, Meng Yonghong, holds 1,032,187 shares, all of which are subject to lock-up[14] - The company’s major shareholder, Zhejiang Yinwan Private Fund Management Co., Ltd., holds 1,362,300 shares through a margin trading account[13] - The company’s total number of unrestricted shares held by the top 10 shareholders is 22,838,309 shares[14] Operational Highlights - The company reported non-recurring gains of ¥726,655.85, primarily from investment income and fair value changes[6] - The company received approval notifications from the National Medical Products Administration for sodium hyaluronate eye drops, ambroxol oral solution, and antiviral tablets during the reporting period[15] - The company obtained an invention patent for the application of Ruixiangsu in the preparation of drugs for treating viral pneumonia on February 11, 2025[17] - The company completed the registration of capital reduction and obtained a new business license on February 24, 2025, reflecting the updated registered capital[18] - The company's inventory increased slightly to ¥28,615,285.00 from ¥27,972,598.48, showing a growth of about 2.3%[19] Revenue and Costs - Total operating costs for the current period were ¥45,150,013.49, down about 14.7% from ¥52,927,049.86 in the previous period[22] - Total revenue from operating activities is 70,019,820.76, slightly decreased from 70,278,576.60 in the previous period[25] - The company reported a net profit margin decline due to reduced revenue and increased operational costs, impacting overall profitability[22]

Financial Performance - The company's operating revenue for 2024 reached ¥256,405,243.38, representing a year-on-year increase of 13.71% compared to ¥225,491,234.57 in 2023[22]. - The net profit attributable to shareholders decreased by 20.26% to ¥40,268,798.73 in 2024 from ¥50,502,418.80 in 2023[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 22.51% to ¥34,746,419.71 in 2024 from ¥28,361,905.28 in 2023[22]. - The total assets at the end of 2024 were ¥1,062,575,503.79, a slight decrease of 0.43% from ¥1,067,195,971.50 at the end of 2023[22]. - The basic earnings per share for 2024 was ¥0.5173, down 17.23% from ¥0.6250 in 2023[22]. - The company reported a cash flow from operating activities of ¥54,243,962.92 in 2024, a marginal decrease of 0.26% compared to ¥54,385,940.66 in 2023[22]. - The company achieved a significant 230.89% increase in other business revenue, rising to ¥1,158,270.72 from ¥350,042.48[72]. - The company's total revenue for 2024 reached ¥256,405,243.38, representing a year-on-year increase of 13.71% compared to ¥225,491,234.57 in 2023[70]. - The main pharmaceutical business generated ¥255,246,972.66, accounting for 99.55% of total revenue, with a growth of 13.37% from ¥225,141,192.09 in the previous year[72]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 2.60 RMB per 10 shares (including tax) to all shareholders[5]. - The total amount for cash dividends and share repurchases in 2024 is expected to be ¥119,886,167.24, representing 297.71% of the net profit attributable to the parent company[197]. - The company plans to distribute a total of ¥391,715,762.62 as available profit for distribution in 2024[195]. Risks and Challenges - The company emphasizes potential risks including policy risks from pharmaceutical system reforms and fluctuations in raw material drug supply and prices[5]. - Environmental protection requirements are increasing operational costs, with potential penalties for non-compliance posing significant risks to production[142]. - Fluctuations in raw material prices, particularly for chemical and traditional Chinese medicine ingredients, could adversely affect the company's profit margins and operational stability[143]. Corporate Governance - The company has established a governance structure that complies with relevant laws and regulations, enhancing transparency and accountability in its operations[150]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with governance standards and effective oversight[153]. - The company has implemented specialized committees to enhance governance, including audit, compensation, and strategic committees, which adhere to legal requirements[154]. - The company has a supervisory board consisting of 5 members, complying with legal requirements and effectively overseeing major matters and financial conditions[155]. - The company emphasizes information disclosure and investor relations, ensuring timely and accurate information is available to all shareholders and investors[156]. Research and Development - The company is focused on expanding its product pipeline in iron supplements and raw materials, aiming to deepen market penetration and enhance brand influence[35]. - The company has 25 registered formulations (32 specifications) and 16 active pharmaceutical ingredient (API) registrations, focusing on anemia treatment, circulatory disorders, and mental health medications[40]. - Research and development expenses increased by 17.52% to ¥10,224,075.45, indicating ongoing investment in innovation[84]. - The company is developing calcium citrate raw materials, with ongoing large-scale production process validation and stability testing for 12 and 18 months, aiming for industrialization and increased sales scale in the raw material market[85]. Market Position and Strategy - The company is positioned in the pharmaceutical manufacturing sector, focusing on the research, production, and sales of chemical drug raw materials and formulations[31]. - The company actively participates in national and regional centralized procurement activities, expanding its market share through competitive pricing and compliance with procurement responsibilities[36]. - The company aims to optimize production processes continuously to ensure high standards and consistency in both APIs and formulations[43]. - The company is committed to complying with new regulations aimed at improving drug pricing transparency and fairness, which may positively impact its market positioning[38]. Employee and Management - The company has a strong commitment to quality management, with a dedicated Quality Director overseeing operations[172]. - The company has a structured approach to compensation, involving human resources and finance departments in the implementation of salary schemes[177]. - The company has a total of 320 employees at the end of the reporting period, with 270 in the parent company and 50 in major subsidiaries[187]. - The company emphasizes the importance of compliance and risk control, establishing a risk warning mechanism to mitigate potential losses[134]. Acquisitions and Investments - The company completed the acquisition of 58.26% of Shuangsheng Pharmaceutical, which will be included in the consolidated financial statements starting December 2024[199]. - The integration of Shuangsheng Pharmaceutical is part of the company's broader strategy for market expansion and product development[199]. - The company has committed to using the raised funds for specific investment projects as promised[109]. Future Outlook - In 2025, the company plans to focus on "innovation-driven, value reshaping, and digital empowerment" as its strategic core, embracing AI pharmaceuticals and green manufacturing to strengthen its competitive edge[118]. - The company aims to enhance its integrated "API + formulation" advantage, optimizing product structure and achieving collaborative development across the industry chain to improve operational efficiency and economic benefits[118].

国泰海通证券股份有限公司 关于吉林省西点药业科技发展股份有限公司 1 | 1.是否按照相关规定建立内部审计制度并设立内部审计部门（如 | √ | | --- | --- | | 适用） | | | 2.是否在股票上市后六个月内建立内部审计制度并设立内部审计 | √ | | 部门（如适用） | | | 3.内部审计部门和审计委员会的人员构成是否合规（如适用） | √ | | 4.审计委员会是否至少每季度召开一次会议，审议内部审计部门 | √ | | 提交的工作计划和报告等（如适用） | | | 5.审计委员会是否至少每季度向董事会报告一次内部审计工作进 | √ | | 度、质量及发现的重大问题等（如适用） | | | 6.内部审计部门是否至少每季度向审计委员会报告一次内部审计 | | | 工作计划的执行情况以及内部审计工作中发现的问题等（如适 | √ | | 用） | | | 7.内部审计部门是否至少每季度对募集资金的存放与使用情况进 | √ | | 行一次审计（如适用） | | | 8.内部审计部门是否在每个会计年度结束前二个月内向审计委员 | √ | | 会提交次一年度内部审计工作计划（如适用） | | | ...